

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 547 530 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
29.06.2005 Bulletin 2005/26

(51) Int Cl.7: **A61B 17/12**

(21) Application number: **04257859.1**

(22) Date of filing: **16.12.2004**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**
Designated Extension States:
AL BA HR LV MK YU

- Lorenzo, Juan A.
Davie Florida 33328 (US)
- Pomeranz, Mark L.
Davie Florida 33325 (US)
- Sherman, Darren
Ft. Lauderdale Florida 33301 (US)

(30) Priority: 17.12.2003 US 738473

(71) Applicant: **Cordis Neurovascular, Inc.**
Miami Lakes, Florida 33014 (US)

(72) Inventors:
• Jones, Donald K.
Lauderhill Florida 33351 (US)

(74) Representative:
Tunstall, Christopher Stephen et al
Carpmaels & Ransford,
43-45 Bloomsbury Square
London WC1A 2RA (GB)

(54) **Activatable bioactive vascular occlusive device and method of use**

(57) A vascular occlusive device (10) which includes a support structure and a bioactive coating (20) disposed onto the support structure and an outer barrier

coating (22) which serves to prevent a reaction between the bioactive agent and bodily fluids until the outer barrier is activated by applying an external agent (30) to the outer barrier.




FIG-2

EP 1 547 530 A1

BEST AVAILABLE COPY

Description

BACKGROUND OF INVENTION

Field of the Invention

[0001] The present invention relates to medical implantable device, and more particularly, to a vascular occlusive device, such as an embolic coil for occluding an aneurysm, which includes a bioactive coating placed on the occlusive device for reacting with bodily tissue in order to promote a desired result, for example promoting an increase of tissue growth into the occlusive device.

Description of the Prior Art

[0002] For many years vasculature occlusive devices have been placed within the vasculature of the human body to occlude, or partially occlude, blood flow through the vasculature. Additionally, such devices have been introduced into aneurysms in order to fill, or partially fill, the aneurysm so as to reduce the pressure which is applied to the interior of the aneurysm in order to prevent further growth or expansion of the aneurysm. These devices may take the form of a coil, such as a helical coil, and are typically placed within the vessel or aneurysm by use of a delivery catheter which is inserted into the vessel and positioned such that the distal end of the delivery catheter is adjacent to a selected site for placement. Once the occlusive device is placed within a blood vessel or aneurysm, surrounding tissue reacts with the "foreign" object and begins to grow into and around the device to provide more complete occlusion of the vessel.

[0003] Examples of such delivery catheters are disclosed in U.S. Patent No. 5,108,407, entitled "Method And Apparatus For Placement Of An Embolic Coil" and U.S. Patent No. 5,122,136, entitled "Endovascular Electrolytically Detachable Guidewire Tip For The Electroformation Of Thrombus In Arteries, Veins, Aneurysms, Vascular Malformations And Arteriovenous Fistulas." These patents disclose catheter systems for delivering embolic coils to preselected positions within vessels of the human body in order to treat aneurysms, or alternatively, to occlude a blood vessel at a preselected location.

[0004] Occlusive devices which take the form of coils may be helically wound coils, random wound coils, coils wound within coils or other such coil configurations. Examples of various coil configurations are disclosed in U.S. Patent No. 5,334,210, entitled, "Vascular Occlusion Assembly" and U.S. Patent No. 5,382,259, entitled, "Vasooocclusion Coil With Attached Tubular Woven Or Braided Fibrous Covering." Such coils are generally formed from radiopaque metallic materials, such as platinum, gold, tungsten or alloys of these metals. Often-times several coils are placed at a given location within a vessel, or within an aneurysm, to more completely oc-

clude, or partially occlude, the flow of blood through the vessel or aneurysm. Thrombus growth onto the coils further enhances the occlusive effect of the coils.

[0005] In the past, embolic coils have been placed within the distal end of a delivery catheter and when the distal end of the catheter is properly positioned, the coil may then be pushed out of the end of the catheter with, for example a guidewire, to release the coil at the desired location. This procedure of placement of the embolic coil is conducted under fluoroscopic visualization such that the movement of the coil may be monitored and the coil may be placed at a desired location.

[0006] In addition, such coils have been specifically designed to be stretch resistant, such as the vasculature occlusive coil disclosed in U.S. Patent No. 5,853,418, entitled, "Stretch Resistant Vaso-Occlusive Coils (II)" which discloses a helically wound coil having a polymeric stretch resistant member extending through the lumen of the coil and fixedly attached to both ends of the coil to prevent the coil from stretching.

[0007] In order to increase the thrombogenicity of an embolic coil, such coils have included a coating, such as collagen, which is applied to the surface of the coil. This concept is disclosed in U.S. Patent No. 5,690,671, entitled, "Embolic Elements And Methods And Apparatus For Their Delivery," which discloses such a collagen coated embolic coil.

[0008] In addition, U.S. Patent No. 5,980,550, entitled, "Water-Soluble Coating For Bioactive Vasoocclusive Devices," discloses an embolic coil having an inner coating which serves as a thrombogenic agent and an outer coating of a water soluble agent which dissolves after placement of the coil in order expose the thrombogenic inner coating to enhance the growth of thrombus into an around the coil.

[0009] The water soluble coating prevents the thrombogenic inner coating from coming into contact with the surrounding blood until the water soluble coating is dissolved by contact with blood which is comprised largely of water.

[0010] While the vasculature occlusive device disclosed in this patent includes an agent for enhancing thrombogenicity of the device and also includes an outer coating to prevent such activity until the outer coating is dissolved by blood flow, there is no control over when the dissolving process begins and therefore no control over the time in which the thrombogenic agent becomes activated. Without such control, it is possible that thrombus can begin forming on the coil prior to the time the coil is properly placed within a vessel, or aneurysm, therefore making it very difficult if not impossible to reposition, or remove, the improperly placed coil. Alternatively, with water soluble outer protective coating the passive process of removing the outer coating may be so slow that the reaction may not occur in a timely manner.

SUMMARY OF THE INVENTION

[0011] In accordance with one aspect of the present invention, there is provided a vascular occlusive device, such as an embolic coil for treating an aneurysm, which includes a support member which may take the form of a helical coil, a bioactive agent which is disposed on the support member, and an outer barrier which is disposed on the bioactive agent to prevent contact between the bioactive agent and a bodily fluid when the vasculature occlusive device is inserted into a blood vessel or aneurysm. The outer barrier exhibits the characteristic of being inert to bodily fluid, but dissolves upon being exposed to an external agent. The external agent may take the form of a liquid medium which may be injected into the blood vessel or aneurysm.

[0012] In accordance with another aspect of the present invention, the bioactive agent takes the form of a coating which is applied to the support member and which serves to enhance a reaction of the body, such as for example the growth of thrombus, into and around the vasculature occlusive device. The outer barrier takes the form of an outer coating applied to the bioactive agent and prevents bodily fluid, such as blood, from reacting with the bioactive agent until such time as the outer barrier is exposed to an external agent. The external agent may take the form of a solvent which when applied to the outer barrier causes the outer barrier to dissolve away from the bioactive agent.

[0013] In accordance with still another aspect of the present invention, there is provided an embolic coil for treating an aneurysm which is coated with a thrombogenic agent, or an agent which increases or promotes the growth of thrombus material, and an outer coating applied to the thrombogenic coating which prevents a reaction between blood and the thrombogenic agent until such time as an external agent is applied to the outer coating to thereby cause this coating to dissolve away from the thrombogenic coating.

[0014] In accordance with still another aspect of the present invention, there is provided a method for treating an aneurysm which includes the steps of inserting a vascular occlusive device which comprises a support member, a bioactive agent disposed on the support member, and an outer coating disposed on the bioactive agent which outer coating exhibits the characteristic of dissolving to uncover at least a portion of the bioactive agent when an external medium is applied to the outer coating. The method also includes the steps of inserting the vascular occlusive device into a blood vessel, or an aneurysm, and, upon election, applying an external medium to the outer coating to thereby cause the outer coating to dissolve and expose at least a portion, or all, of the bioactive agent to thereby cause a desired reaction between the body and the vascular occlusive device.

[0015] In accordance with still another aspect of the present invention, the method includes the steps of pro-

viding a vasculature occlusive coil which has a thrombus inducing surface and which is coated with an outer coating which exhibits the characteristics of dissolving to expose at least a portion of the thrombogenic material when an external agent is applied to the outer coating. This method step also includes the steps of inserting the vasculature occlusive device into a blood vessel or an aneurysm, and then upon election, applying an external agent to the outer coating to thereby cause the outer coating to dissolve and expose at least a portion of the thrombogenic surface of the vasculature occlusive device.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016]

Figure 1 is an elevational view of an embolic coil illustrating a vascular occlusive coil in accordance with one embodiment of the present invention;

Figure 2 is an elevational view, partly in cross-section of the vascular occlusive coil as shown in Figure 1 illustrating a bioactive coating and an outer barrier coating in accordance with the embodiment of the present invention;

Figures 3A through 3C illustrate the method steps of applying multiple vascular occlusive coils as shown in Figure 1 into an aneurysm and thereafter applying an external agent to thereby activate the embolic coils.

DESCRIPTION OF THE PREFERRED EMBODIMENT

[0017] Figures 1 and 2 illustrate a vascular occlusive device which takes the form of an embolic coil 10 which may be placed along with other similar coils into a blood vessel or into an aneurysm in order to partially fill the aneurysm. More particularly, the embolic coil 10 is a typical embolic coil which comprises a helically wound coil 12 formed from a platinum alloy wire wound into a helical configuration. The diameter of the wire is generally in the range of about 0.0007 inches to about 0.008 inches and the outer diameter of the coil 12 is preferably in a range of about 0.003 inches to about 0.055 inches. While the particular embolic coil 12 illustrated in Figures 1 and 2 is shown as being a straight, helically wound coil, it should be appreciated that embolic coils are formed in various configurations and may take the form of a helix, a random shaped configuration or even a coil within a coil.

[0018] Preferably the embolic coil 10 includes a weld bead 14 which is attached to the distal end of the coil for providing a less traumatic distal end for the embolic coil 10. In addition, the embolic coil 10 includes a cylindrical headpiece 16 which is placed into the lumen of the helically wound coil 12 at the proximal end of the coil and is held in place by an adhesive material 18 interposed between the cylindrical headpiece 16 and the hel-

ical coil 12. The construction of the embolic coil 10 and an associated hydraulic deployment system for placing the embolic coil within an aneurysm is disclosed in more detail in U.S. Patent Application Serial No. 10/102,154, entitled, "Small Diameter Embolic Coil Hydraulic Deployment System," filed March 19, 2002, assigned to the same assignee of the present invention and is hereby incorporated by reference.

[0019] Figure 2 illustrates in more detail a bioactive agent 20, and an outer barrier 22 which is disposed upon the bioactive agent 20 for preventing the activation of the bioactive agent until such time as an election is made to activate the bioactive agent. More particularly, the bioactive agent 20, which may take the form of a thrombogenic agent, i.e. an agent which serves to increase or promote the growth and adhesion of thrombus onto the surface of the embolic coil 10, is coated onto the outer surface of the coil 12. While the bioactive agent may take the form of a thrombogenic agent, it should be understood that the bioactive agent may take any form which would induce a desired reaction bodily tissue. For example, the bioactive agent may serve to cause blood to clot onto the surface of the embolic coil 10, it may serve to enhance the adhesion of thrombus onto the surface of the embolic coil, or it may serve to cause adjacent embolic coils to become bonded to each other through adhesion by components of blood. It should be appreciated that there are many other reactions which might exist between the bioactive agent and bodily tissue which would be desirable.

[0020] The outer barrier 22 takes the form of a coating which is disposed upon the bioactive agent 20 and serves to insulate the bioactive agent from adjacent bodily fluid until such time as a decision is made by a physician to activate the outer barrier 22. The outer barrier 22 takes the form of a material which is inert to bodily fluid, but which dissolves and exposes the bioactive agent 20 when the outer barrier 22 is subjected to an external agent.

[0021] In a preferred embodiment, the bioactive agent 20 is comprised of polyglycolic acid, the outer barrier 22 is comprised of ethylene vinyl alcohol and the external agent for dissolving the outer barrier 22 is dimethyl sulfoxide (DMSO) which serves to dissolve the outer barrier 22 to thereby expose the bioactive agent 20.

[0022] It should be appreciated that there are numerous materials which would serve as a bioactive agent, an outer barrier and an external agent, some of which are indicated hereinafter. It is important, however, that the external agent be inert to bodily fluids, such as being non-water soluble, such as blood, in order to prevent the outer barrier 22 from dissolving and exposing the bioactive agent 20 until such time as an election is made by a physician to activate the outer barrier 22.

[0023] Figures 3A through 3C generally illustrate a method of utilizing the present invention. More particularly, Figure 3A illustrates a delivery catheter 24 having an embolic coil 10 placed in the distal end of the catheter

for delivery into an aneurysm 26. Figure 3B illustrates the delivery catheter 24 being used to position multiple vascular occlusive coils including a final embolic coil 28 into the aneurysm 26. Figure 3C illustrates the application of an external agent 30, which may take the form of a solvent for dissolving the outer barrier 22 to thereby activate the outer barrier 22 to expose at least a portion of the bioactive agent 20.

[0024] It may be desirable to place all of the vascular occlusive coils into the aneurysm 26 prior to applying the external agent 30, however, another approach is that of placing a single coil into the aneurysm and thereafter activating that single coil, placing a second coil into the aneurysm and thereafter activating the second coil and so forth until all of the coils have been properly placed into the aneurysm. As may be appreciated, the advantage of the subject invention over prior devices is that the physician may determine at what point in time during the process of "filling" an aneurysm the physician elects to activate a coil as opposed to having no control over the time in which the coils become activated.

[0025] The bioactive agent may take the form of any material or surface which when placed into the body causes or inhibits a reaction with a bodily substance. For example, the bioactive agent may be a thrombus inducing material, or surface when placed within a blood vessel induces the growth of thrombus onto the surface of the bioactive agent or where the bioactive agent is a thrombolytic agent to inhibit the growth of tissue. The bioactive agent could take the form of a material which causes blood to clot onto the surface of the material, a material which produces an immune response, a material which releases a human growth factor, a material which promotes endothelization, etcetera. Another example of a bioactive agent is a pharmacologic agent which is inactive until the barrier is dissolved, or removed, or is modified, by an external source to expose the pharmacological agent to the body. A preferred bioactive agent to be used with a vascular occlusive coil is polyglycolic acid which promotes the growth of tissue.

[0026] The outer barrier may take the form of a coating applied to the bioactive agent, or a substance added to the bioactive agent, which causes the bioactive agent to be substantially non-reactive with bodily fluids until such time as the outer barrier is acted upon by an external agent. A preferred outer barrier to be used with a vascular occlusive coil is a coating of ethylene vinyl alcohol which serves to encase the bioactive agent until a solvent is applied to the coating to thereby dissolve, or remove, or modify the barrier in order to expose the bioactive agent to the body.

[0027] The external agent may take the form of any agent which when applied to the outer barrier causes the outer barrier to become ineffective in preventing a reaction between the bioactive agent and bodily tissue. The external agent may take the form of a solvent for dissolving the outer barrier in order to expose the bioactive agent, or it may take the form of a substance

which reacts with the bioactive agent in order to activate the bioactive agent. The external agent may for example be a liquid material or it may be a source of heat or a laser source for dissolving the outer barrier, or removing all or part of the outer barrier or for modifying the outer barrier such as for example biologically modifying the outer barrier in order to activate receptors of the bioactive agent, in order to expose the bioactive agent to bodily tissue. A preferred external agent for a vascular occlusive coil is dimethyl sulfoxide which serves as a solvent to dissolve an outer barrier coating comprising ethylene vinyl alcohol so as to permit the bioactive agent to come into contact with bodily tissue. By "bodily tissue" is meant any substance within the human body and includes blood, fibrous growth within blood vessels, etcetera.

[0028] Although a preferred embodiment of the present invention has been described, it is to be understood that various modifications may be made by those skilled in the art without departing from the scope of the claims which follow.

Claims

1. A vascular occlusive device comprising:
 - a support member;
 - a bioactive agent disposed on said support member; and,
 - an outer barrier disposed on said bioactive agent to prevent exposure of said bioactive agent to bodily fluid when said vascular occlusive device is inserted into a blood vessel, said outer barrier exhibiting the characteristic of being substantially inert to bodily fluid but dissolving when exposed to an external agent.
2. A vascular occlusive device as defined in Claim 1, wherein the support member is a vascular occlusive embolic coil.
3. A vascular occlusive device as defined in Claim 2, wherein the support member takes the form of a helically wound metallic coil.
4. A vascular occlusive device as defined in Claim 1, wherein the bioactive agent takes the form of a coating applied to the support member.
5. A vascular occlusive device as defined in Claim 1, wherein the bioactive agent is integral with the support member.
6. A vascular occlusive device as defined in Claim 1, wherein the outer barrier takes the form of a coating applied to the bioactive agent.
7. A vascular occlusive device as defined in Claim 2, wherein the outer barrier coating takes the form of a coating applied to the bioactive agent.
8. A vascular occlusive device as defined in Claim 1, wherein said bioactive agent is comprised of polyglycolic acid and said outer barrier coating is comprised of ethylene vinyl alcohol.
9. A vascular occlusive device as defined in Claim 8, wherein said external agent is comprised of dimethyl sulfoxide.
10. A vascular occlusive device as defined in Claim 1, wherein said bioactive agent takes the form of a thrombus inducing coating.
11. A vascular occlusive device as defined in Claim 2, wherein said bioactive agent takes the form of a thrombus inducing coating.
12. A vascular occlusive device comprising:
 - a support member;
 - a bioactive agent disposed on said support member; and,
 - an outer barrier coating disposed on said bioactive agent to prevent exposure of said bioactive agent to bodily fluid when said vascular occlusive device is inserted into a blood vessel, said outer barrier coating exhibiting the characteristic of being non-water soluble but dissolving when an external activating agent is applied to said outer barrier coating.
13. A vascular occlusive device comprising:
 - a support member;
 - a bioactive agent disposed on said support member; and,
 - an outer barrier disposed on said bioactive agent to prevent contact between said bioactive agent and bodily fluid when said vascular occlusive device is inserted into a blood vessel, said outer barrier exhibiting the characteristic of being substantially inert to blood but dissolving and exposing a portion of said bioactive agent when in the presence of a biological agent.
14. A vascular occlusive device comprising:
 - a support member;
 - a bioactive agent disposed on said support member; and,
 - an outer barrier comprising an activatable agent, said outer barrier covering said bioactive agent and exhibiting the characteristics of sub-

stantially preventing a reaction between the bioactive agent and bodily fluid when said vascular occlusive device is inserted into a blood vessel and permitting a reaction between the bioactive agent and bodily fluid upon activation by an external source. 5

15. A vascular occlusive device comprising:

a bioactive support member which when placed within the body causes a reaction with bodily tissue; and, 10
a barrier for preventing a reaction between the bioactive support member and bodily tissue when said vascular occlusive device is inserted into a blood vessel, said barrier exhibiting the characteristic of being non-water soluble but exposing the bioactive support member to bodily tissue when an activating agent is applied to said barrier. 15 20

16. A vascular occlusive device comprising:

a support member which when placed within the body causes a reaction with bodily tissue; 25
and,
a barrier for preventing a reaction between the support member and bodily fluid when said vascular occlusive device is inserted into a blood vessel, said barrier exhibiting the characteristic of exposing a portion of said support member when in the presence of an external agent. 30

35

40

45

50

55




FIG - 1




FIG - 2




FIG - 3A




FIG - 3B




FIG - 3C



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 04 25 7859

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,Y	US 5 980 550 A (EDER ET AL) 9 November 1999 (1999-11-09) * columns 3,6; figure 2 *	1-7,9-16	A61B17/12
Y	US 2003/017190 A1 (SIRHAN MOTASIM ET AL) 23 January 2003 (2003-01-23) * paragraphs [0025] - [0027], [0029], [0063] - [0065], [0070]; figures 8,9 *	1-7,9-16	
Y	EP 1 369 137 A (MITCHNICK, MARK) 10 December 2003 (2003-12-10) * column 11, lines 21-25 *	1-3, 10-16	
A	WO 02/083039 A (ADVANCED CARDIOVASCULAR SYSTEMS, INC) 24 October 2002 (2002-10-24) * paragraphs [0044], [0045], [0048] *	1,12-16	
A	US 6 599 275 B1 (FISCHER, JR. FRANK J) 29 July 2003 (2003-07-29) * paragraph [0035]; figure 1 *	1,12-16	
A	US 5 695 480 A (EVANS ET AL) 9 December 1997 (1997-12-09) * column 4, lines 58-64 - column 6, lines 7-12 *	8,9	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61B A61L
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 11 April 2005	Examiner Assion, J-C
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

2
EPO FORM 1503 (03.02) (P04CO1)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 04 25 7859

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-04-2005

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5980550 A	09-11-1999	AU 4568699 A	05-01-2000
		DE 69919355 D1	16-09-2004
		EP 1087703 A1	04-04-2001
		WO 9965401 A1	23-12-1999
		US 6299627 B1	09-10-2001
		US 2002087184 A1	04-07-2002
US 2003017190 A1	23-01-2003	US 2002114823 A1	22-08-2002
		EP 1355588 A2	29-10-2003
		JP 2004523275 T	05-08-2004
		WO 02056790 A2	25-07-2002
		US 2003033007 A1	13-02-2003
		US 2003050692 A1	13-03-2003
		US 2003139801 A1	24-07-2003
		US 2002082679 A1	27-06-2002
		US 2002082677 A1	27-06-2002
		US 2002082685 A1	27-06-2002
EP 1369137 A	10-12-2003	US 2003229319 A1	11-12-2003
		AU 2003204552 A1	08-01-2004
		CA 2430977 A1	05-12-2003
		EP 1369137 A1	10-12-2003
WO 02083039 A	24-10-2002	US 6764505 B1	20-07-2004
		WO 02083039 A1	24-10-2002
		US 2004191404 A1	30-09-2004
US 6599275 B1	29-07-2003	US 2004068241 A1	08-04-2004
		AU 716764 B2	09-03-2000
		AU 3294497 A	05-01-1998
		CA 2239089 A1	11-12-1997
		DE 69714994 D1	02-10-2002
		DE 69714994 T2	30-04-2003
		DK 906129 T3	02-12-2002
		EP 0906129 A1	07-04-1999
		ES 2183191 T3	16-03-2003
		JP 2000511450 T	05-09-2000
		WO 9746268 A1	11-12-1997
US 5695480 A	09-12-1997	AT 269121 T	15-07-2004
		AU 2814697 A	20-02-1998
		CA 2260047 A1	05-02-1998
		DE 69729569 D1	22-07-2004
		EP 0923399 A1	23-06-1999
		JP 2000517298 T	26-12-2000

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 04 25 7859

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-04-2005

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5695480	A	WO 9804312 A1	05-02-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.